# Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma

> **NCT05626985** · — · UNKNOWN · sponsor: **Singlera Genomics Inc.** · enrollment: 2000 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** GAMAD

## Key facts

- **NCT ID:** NCT05626985
- **Lead sponsor:** Singlera Genomics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-19
- **Primary completion:** 2024-10
- **Final completion:** 2024-12
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2024-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626985, "Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05626985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*